Antibody Blockade of the Luteinizing Hormone Receptor for the Treatment of Prostate Cancer (Epstein/Pinski Co-PI)
The major aim of this proposal is to produce an antagonistic antibody to the human Luteinizing Hormone Receptor (LHR) for the immunotherapy of prostate cancer. Previously, we have demonstrated that LHR signaling can increase the expression of key steroidogenic genes and that silencing LHR by siRNA significantly reduces prostate cancer proliferation. To produce a clinically relevant reagent to inhibit prostate cancer growth via LHR blockade, a monoclonal antibody will be produced using a genetically engineered LHR-Fc and tested both in vitro and in vivo for its anti-tumor potential.

NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.